HEPATOBILIARY DISEASE ORIENTED GROUP

CHELSEA HOTEL, TORONTO, ON
ROOM: NAME: ROSSETTI
SATURDAY APRIL 28, 2018, 3:00 PM – 4:00 PM

CO-CHAIRS : DR. JENNIFER KNOX AND DR. OLIVER BATHE
SENIOR INVESTIGATOR: DR. CHRIS O’CALLAGHAN

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
• To interpret and address, through clinical and translational research, the disease burden associated with hepatobiliary malignancies in Canada.
• To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to hepatobiliary malignancies.
• To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to hepatobiliary malignancies.
• To interpret and apply new clinical trial methodologies in the field of clinical research in hepatobiliary malignancies.

3:00 pm  Setting Strategic Plan  Dr. O. Bathe
Active/Recently Closed Trials for Update  Dr. O. Bathe
3:20 pm  HE. 1: Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases  Dr. R. Wong
Approved Trials in Development
3:25 pm  Bl. 3 Phase II/III Trial Comparing Acelarin plus Cisplatin to Gemcitabine Plus Cisplatin in First-Line Treatment of Locally Advanced or Metastatic Biliary Cancer  Dr. C. O’Callaghan
New Concepts in Development
3:35 pm  SWOG Gemcitabine and Capecitabine vs Capecitabine +/- Radiotherapy in R1 Resected Adjuvant Biliary Cancer  Dr. O. Bathe
3:45 pm  Sequential vs combination Immunotherapy and TKIs in HCC  Dr. V. Tam
3:55 pm  Intergroup Task Force Update  Dr. O. Bathe
4:00 pm  Meeting adjourned